PGR and metastatic neoplasm: These included differences between treatment groups in the Japanese subpopulation (e.g., a higher proportion of patients had ECOG PS = 1 and progesterone receptor-positive status in the abemaciclib arm) and between the Japanese subpopulation and the overall population (e.g., no Japanese patients had de novo metastatic disease compared with nearly 40% in the overall population; 58.5% in the Japanese subpopulation had received prior ET compared with 46.7% in the overall population).